Monitor SYMON-II completion and subsequent FDA 510(k) submission as key catalysts. Cash runway limited (~$3.7M) suggests potential need for financing within ~2 quarters.
Price Chart
Executive Summary
Bluejay Diagnostics provided a Q1 2026 corporate update highlighting continued enrollment in its SYMON-II pivotal study and manufacturing progress with Sanyoseiko. Financial results show a net loss of ~$1.9M and cash of $3.7M, consistent with prior quarters and pre-revenue stage. No material financial catalysts were announced.
Key Financial Metrics
Key Facts
- SYMON-II pivotal study enrollment at ~680 of 750 target patients as of May 5, 2026
- Cash and cash equivalents of ~$3.7M as of March 31, 2026
- Net loss of ~$1.9M for Q1 2026, flat vs Q1 2025
- Technical issues resolved with Symphony cartridge manufacturing; advancing toward analytical and clinical validation
- No revenue reported; company remains pre-revenue
Financial Impact
No material financial impact; net loss unchanged at ~$1.9M, cash burn continues
Risk Factors
- Cash runway may be insufficient to complete regulatory and clinical milestones without additional financing
- Regulatory clearance for Symphony IL-6 test is uncertain and subject to FDA review
- No revenue; stock relies on binary clinical/regulatory events
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290498 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | $0.8323 | awaiting T+20 | — | $0.5770 (−30.67%) |
Oct 6, 2026 21d ago | 8-K | $0.8107 | awaiting T+20 | — | $0.5770 (−28.83%) |
Aug 13, 2026 10w ago | 8-K | $1.06 | awaiting T+20 | — | $0.5770 (−45.57%) |
Aug 13, 2026 10w ago | Press Release | $1.06 | awaiting T+20 | — | $0.5770 (−45.57%) |
Jul 22, 2026 13w ago | 8-K | $1.14 $0.9393 | ▼ −17.61% | ▼ −20.91% | $0.5770 (−49.39%) |
Jul 13, 2026 15w ago | 3 | $1.22 $0.9872 | ▼ −19.08% | ▼ −22.27% | $0.5770 (−52.70%) |
Jul 10, 2026 15w ago | 3 | $1.45 $1.07 | ▼ −26.21% | ▼ −28.63% | $0.5770 (−60.21%) |
Jun 29, 2026 17w ago | EFFECT | $1.44 $1.03 | ▲ +28.47% | ▲ +28.19% | $0.5770 (+59.93%) |
Jun 17, 2026 18w ago | S-3 | $4.46 $1.30 | ▲ +70.85% | ▲ +71.39% | $0.5770 (+87.06%) |
Jun 9, 2026 20w ago | 8-K | $4.49 $1.40 | ▼ −68.82% | ▼ −72.44% | $0.5770 (−87.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers